

April 23, 2021

FOR IMMEDIATE RELEASE

Company name:	H.U. Group Holdings, Inc.
Representative:	Shigekazu Takeuchi, Director, President
	and Group CEO
Securities code:	4544 First Section, Tokyo Stock Exchange

H.U. Group Begins sale of Research Assay Reagents and Undertaking of Research Tests for Detecting IgG Antibodies for the Novel Coronavirus's Spike Protein

Fujirebio Inc. (President & CEO: Takeshi Fujita; Head Office: Shinjuku-ku, Tokyo; hereinafter "Fujirebio"), which is a consolidated subsidiary of H.U. Group Holdings, Inc., has commenced sale of a research assay reagent (hereinafter, the "Reagent") for IgG antibodies for the S (spike) protein of the novel coronavirus (SARS-CoV-2) as of April 23, 2021, under the product name of SARS-CoV-2 S-IgG (IB).

The Reagent is a dedicated reagent for use with the LUMIPULSE[®] L2400 and LUMIPULSE[®] Presto II, fully automated CLEIA (chemiluminescent enzyme immunoassay) instrument systems, also provided by Fujirebio.

SRL, Inc. (President & CEO: Shunichi Higashi; Head Office: Shinjuku-ku, Tokyo), also a consolidated subsidiary of H.U. Group Holdings, Inc., plans to start undertaking research tests using the Reagent around the middle of May 2021.

Moving forward, the H.U. Group will continue working to develop reagents for novel coronavirus antibody tests.

End.

Product Overview

Product Name	SARS-CoV-2 S-IgG (IB)
Antibodies to Be Detected	IgG antibodies for the SARS-CoV-2 S (spike) protein
Start of Sales	April 23, 2021
Supported Devices	LUMIPULSE [®] L2400, LUMIPULSE [®] Presto II
Processing Capacity	240 tests per hour
Test Duration	Approx. 25 min.
Product Image	

To inquire about this announcement, please use the contact information below.	
<for institutions="" medical=""> Fujirebio Inc. Call Cantar Dhanay 0120, 202, 822 (tall free in Japan only weekdays 08:00, 20:00)</for>	
Call Center Phone: 0120-292-832 (toll-free in Japan only weekdays 08:00–20:00)	
For members of the media:	
Public Relations Section, Corporate Communications Dept.	
Phone: +81-3-6279-0884	
Email: <u>pr@hugp.com</u>	
For investors and analysts:	
IR/SR Section, Corporate Communications Dept.	
Phone: +81-3-5909-3337	
Email: <u>ir@hugp.com</u>	